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ABSTRACT
Introduction: This study aimed to describe clinical trials approved by the Brazilian 
Health Surveillance Agency (ANVISA) and coordinated by federal university hospitals 
(FUHs), as well as to investigate the relationship between the number of clinical trials 
and the assistance provided by these FUHs.
Methods: This is a cross-sectional study based on data obtained from the ANVISA 
clinical trial consultation system. The National Register of Health Care Facilities and 
the Ambulatory Care Information System of the Unified Health System (SUS) were 
used as sources of information on the assistance provided by FUHs, such as the mean 
number of specialized medical consultations and the number of beds. Scatter plot 
and Spearman’s correlation coefficient analyses were used to verify the association 
between these aspects of FUHs and the number of clinical trials.
Results: Between 2012 and 2013, ANVISA authorized 209 trials to be coordinated by 
23 FUHs; 75% of the trials were coordinated by 7 FUHs, 69.8% were phase III trials, 
and 94% were multicenter studies. The number of clinical trials presented positive 
and statistically significant associations with the mean number of specialized medical 
consultations and the number of beds (Spearman’s correlation coefficients r = +0.70 
and r = +0.64, respectively).
Conclusion: FUHs have a leadership role in the conduction of clinical trials in Brazil, 
but showed heterogeneity regarding their assistance capacities and the number of 
clinical trials. A predominance of phase III trials may be interpreted as a low use of 
the scientific potentiality of these facilities.
Keywords: University hospitals; teaching hospitals; clinical trial; Brazilian Health 
Surveillance Agency
INTRODUCTION
Federal university hospitals (FUHs) are part of federal universities and 
are committed to a tripartite mission of health care, research, and teaching. 
Their financial sources are the Brazilian Ministries of Health and Education1. 
In 2011, the federal government created the Brazilian Company of Hospital 
Services (EBSERH), a government-sponsored enterprise, to improve 
management and increase and qualify the workforce of these hospitals2. 
In 2013, there were 47 FUHs linked to 35 federal universities, of which 21 had 
an agreement with EBSERH3. In 2019, out of 50 FUHs linked to 35 federal 
universities, 40 had EBSERH participating in their management.
FUHs represent 2% of the national public hospital network and account 
for 3.3% of the beds available in the Unified Health System (SUS)4. According 
to the Directory of Research Groups of the National Council for Scientific and 
Technological Development (CNPq), approximately half of the current research 
groups in health sciences are based in federal universities and their hospitals5.
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Clinical trials involve research using human volun-
teers for testing the efficacy and safety of interventions 
using medical products, such as drugs or devices, 
or changes to participants’ behaviors, such as diets. 
These studies aim to produce scientific knowledge 
to improve health care. These types of studies are 
classified according to the phase of development of 
the interventions being studied. Phase I trials assess 
product safety in healthy individuals; phase II trials 
analyze the safety and efficacy of the product by 
comparison to another product or a placebo within 
a small and homogeneous group of individuals with 
the disease under study; phase III trials repeat this 
assessment in a larger and more varied group of 
sick individuals; finally, phase IV trials are performed 
after commercialization and monitor adverse 
effects or events6.
Many clinical trials are performed in FUHs and 
their protocols and results are among the documents 
required by regulatory bodies to support the decision 
on its registration. The approval of clinical trials 
with the aim of registering drugs and products 
for commercialization in Brazil is subject to the 
authorization of the Brazilian Health Surveillance 
Agency (ANVISA)7, the institution’s Research Ethics 
Committee (CEP), and the National Commission of 
Ethics in Research of the National Health Council 
(CONEP/CNS)8.
According to ClinicalTrials.gov, around 311 000 
clinical trials were registered worldwide from 1997 to 
2019. North American studies corresponded for 44% 
of these trials, European trials represented 29%, 
East Asian studies accounted for 11%, and South 
American studies were 3.2%. Brazil hosted 70% 
of approximately 10,000 registered clinical trials in 
South America, representing 2.3% of the global total9. 
Industry Standard Research reports indicate that 
global investments on clinical research in 2018 were 
of around US$ 124 billion and should reach almost 
US$ 133 billion in 202110. 
In 2014, the EBSERH Strategic Clinical Research 
Program for SUS (EpecSUS) was created for 
implementing a model for clinical research management 
within FUHs11. This program was expected to 
promote the institutionalization, transparency, and 
effectiveness of the trial approval process, as well 
as the development, budgetary execution, and 
monitoring of clinical research in compliance with 
Good Clinical Practices (GCP)12. EpecSUS also 
aimed to promote clinical research considering 
themes that were strategic for the SUS.
Our study aimed to describe the clinical trials 
approved by ANVISA to be coordinated by FUHs 
and to investigate the association between the 
number of clinical trials and the assistance provided 
by these FUHs.
METHODS
This is a cross-sectional, retrospective study 
that used information retrieved from the ANVISA 
clinical trial consultation system. This system can be 
accessed by filling at least two of the following fields: 
protocol title, protocol code, name of drug or product 
under study, disease for which the drug or product 
will be prescribed (following the International 
Statistical Classification of Diseases and Related 
Health Problems, 10th revision [CID-10]), date of 
trial authorization, process number, and Special 
Notice number13.
With the collaboration of ANVISA’s Clinical Research 
Management (GEPEC), EBSERH obtained the titles 
of clinical trials authorized to be coordinated by 
FUHs from January 1, 2012 to December 31, 2013. 
Searching the database by title and date of 
authorization, we obtained the therapeutic class of 
the tested product, CID-10, protocol code, and phase 
of the clinical trial.
The FUH service was assessed according to the 
numbers of beds and specialized medical consults 
conducted in 2012 and 2013. These data were 
collected from the National Register of Health Care 
Facilities (CNES) and the SUS Ambulatory Care 
Information System/Tabwin (SIA)14 between October 
and December 2014.
Data were described by means of absolute 
and relative frequencies, standard deviations, and 
variation coefficients. An association between the 
number of clinical trials and the assistance provided 
by FUHs was investigated through a scatter plot and 
the Spearman’s correlation coefficient test; statistical 
significance considered p < 0.05.
This study was based on secondary and public 
domain data; therefore, it was not submitted to a CEP 
in accordance with the CNS Resolution No. 466/20128.
RESULTS
According to GEPEC/ANVISA, 209 clinical trials 
(95 in 2012 and 114 in 2013) were authorized for 
conduction in 23 FUHs. These trials corresponded 
to 45% of all trials approved by ANVISA in this 2-year 
period. Out of these 23 hospitals, 7 were responsible 
for the coordination of three-quarters (n = 157) of the 
authorized trials.
Table 1 presents the selected metrics of hospital 
care and the number of clinical trials authorized per 
hospital. The number of beds varied from 15 to 687 
(mean: 312), and the mean number of specialized 
medical consultations was 178 000, ranging from 
8190 and 1 020 000. Each FUH coordinated up to 
34 trials (mean: 9). The characteristics of the analyzed 
hospitals were highly heterogeneous. 
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Table 1: Federal university hospitals: numbers of beds and specialized medical consultations compared to the number 
of clinical trials authorized by the Brazilian Health Surveillance Agency (ANVISA) between 2012 and 2013.
Hospital* No. of beds No. of specialized consultations 2012
No. of specialized 
consultations 2013 No. of clinical trials
HCPA/UFRGS 687 374 177 406 424 34
HC/UFPR 474 352 001 337 216 29
HC/UFG 384 125 595 146 178 21
HSP/UNIFESP 522 606 726 14 32992 21
HC/UFMG 511 245 382 257 122 19
HUCFF/UFRJ 471 239 047 216 168 18
HUPES/UFBA 353 19 1555 191 457 14
HUGG/UNIRIO 158 94 355 81 488 9
HUJBB/UFPA 284 99 945 83 685 8
HUWC/UFC 248 123 281 137 181 8
HUB/UNB 268 114 746 108 262 7
HC/UFPE 342 135 724 162966 4
IP/UFRJ 117 40 571 37 566 3
HUCAM/UFES 306 150 702 172 981 3
HU/UFMA 573 168 400 156 429 2
HUMAP/UFMS 257 80 925 72 007 2
HUPEST/UFSC 392 92 171 98 285 1
HUAP/UFF 256 145 797 154 450 1
HE/UFTM 299 122 114 109 928 1
HU/UFJF 140 76 508 84 269 1
IPPMG/UFRJ 69 49 283 51 443 1
HESFA/UFRJ 15 96 18 6 759 1
INDC/UFRJ 40 18 070 19 266 1
Total 209
*HCPA/UFRGS: Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul; HC/UFPR: Hospital de Clínicas, Universidade 
Federal do Paraná; HU/UFG: Hospital Universitário, Universidade Federal de Goiás; HSP/UNIFESP: Hospital São Paulo, Universidade Federal 
de São Paulo; HC/UFMG: Hospital de Clínicas, Universidade Federal de Minas Gerais; HUCFF/UFRJ: Hospital Universitário Clementino 
Fraga Filho, Universidade Federal do Rio de Janeiro; HUPES/UFBA: Hospital Universitário Prof. Edgard Santos, Universidade Federal da 
Bahia; HUGG/UNIRIO: Hospital Universitário Gaffrée e Guinle, Universidade Federal do Estado do Rio de Janeiro; HUJBB/UFPA: Hospital 
Universitário João de Barros Barreto, Universidade Federal do Pará; HUWC: Hospital Universitário Walter Cantídio, Universidade Federal do 
Ceará; HUB/UNB: Hospital Universitário, Universidade de Brasília; HC/UFPE: Hospital das Clínicas, Universidade Federal de Pernambuco; 
IP/UFRJ: Instituto de Psiquiatria, Universidade Federal do Rio de Janeiro; HUCAM/UFES: Hospital Universitário Cassiano A. de Moraes, 
Universidade Federal do Espírito Santo; HU/UFMA: Hospital Universitário, Universidade Federal do Maranhão; HUMAP/UFMS: Hospital 
Universitário Maria Aparecida Pedrossian, Universidade Federal de Mato Grosso do Sul; HUPEST/UFSC: Hospital Universitário Polydoro E. 
de São Thiago, Universidade Federal de Santa Catarina; HUAP/UFF: Hospital Universitário Antônio Pedro, Universidade Federal Fluminense; 
HE/UFTM: Hospital Escola, Universidade Federal do Triângulo Mineiro; HUJF/UFJJ: Hospital Universitário, Universidade Federal de Juiz de 
Fora; IPPMG/UFRJ: Instituto de Puericultura e Pediatria Martagão Gesteira, Universidade Federal do Rio de Janeiro; HESFA/UFRJ: Hospital 
Escola São Francisco de Assis, Universidade Federal do Rio de Janeiro; INDC/UFRJ: Instituto de Neurologia Deolindo Couto, Universidade 
Federal do Rio de Janeiro.
Considering the numbers of specialized medical 
consultations and beds as metrics indicating hospital 
size, the scatter plot (Figure 1) illustrated a positive 
correlation between the number of clinical trials and 
the size of FUHs, that is, bigger hospitals coordinated 
more trials. The Spearman’s correlation coefficient was 
r = +0.64 for the relationship between the numbers of beds 
and clinical trials. Regarding the relationship between 
the mean number of consultations and the number of 
clinical trials, the Spearman’s correlation coefficient was 
r = +0.70. Both were statistically significant (p < 0.05).
All the evaluated clinical trials were conducted 
to assess the safety and efficacy of drugs. Figure 2 
depicts the frequency distribution of drug therapeutic 
classes; this information was not available for 28 (13%) 
of the 209 clinical trials. Antineoplastic, antidiabetic, 
antiviral, and immunosuppressive drugs were the 
predominantly tested pharmacological groups. 
The therapeutic classes with frequencies smaller 
than 10 were grouped into the “other therapeutic 
classes” category, representing 49% of the evaluated 
clinical trials.
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Figure 1: Correlation between number of clinical trials, specialized medical consultations, and number of beds
Figure 2: Frequency distribution of drug therapeutic classes
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Table 2 shows the diseases (classified according 
to CID-10) for which the drugs were tested in 199 
trials with available information. Endocrine diseases, 
neoplasms, and viral infections were the object of study 
in half of the clinical trials. Neoplasms, considering 
in situ and benign neoplasms, represented the most 
studied disease group (almost one-quarter of the trials).
The classification of clinical trials according to 
the phase of clinical development is presented in 
Table 3. We observed that the majority (69.8%) 
were phase III studies and 94% of the trials were 
multicenter. This information was not available for 
10 of the evaluated trials.
Table 2: Number of clinical trials by groups of diseases 
targeted by the tested drugs.
Disease groups* No. (%)
A – Infectious Diseases: 
tuberculosis
1  (0.5)
B – Viral infections characterized 
by lesions of the skin and mucosa, 
hepatitis; human immunodeficiency 
virus disease
22 (11.1)
C – Neoplasms 40 (20.1)
D – In situ neoplasms and 
benign neoplasms
8  (4.0)
E – Nutritional and metabolic 
endocrine diseases
41 (20.6)
F – Mental disorders 7 (3.5)
G – Nervous system diseases 13  (6.5)
H –Diseases of the eye 
and its annexes
8 (4.0)
I – Circulatory system diseases 15 (7.5)
J – Respiratory system diseases 16 (8.0)
K – Digestive system diseases 3 (1.5)
L – Skin and subcutaneous 
tissue diseases
4 (2.0)
M – Diseases of the osteomuscular 
system and conjunctive tissue
14 (7.0)
N – Genitourinary system diseases 4 (2.0)
P – Affections of the 
perinatal period
2 (1.0)
Z – Factors that influence health 




*Disease groups according to the International Statistical 
Classification of Diseases and Health-Related Problems – 10th 
revision (CID-10).
**This information was not available for 10 of the clinical trials.
Table 3: Number of clinical trials according to their 
development phases.






*This information was not available for 10 of the clinical trials.
DISCUSSION
Even though FUHs account for a small fraction of 
the public health care network, they coordinated 45% of 
the clinical trials authorized by ANVISA between 2012 
and 2013, playing an important role in the Brazilian 
process of registration and commercialization of new 
therapeutic products. We also found a significant 
heterogeneity in the number of trials per FUH. 
These trials most frequently studied endocrine and 
metabolic diseases, neoplasms, and viral infections, 
and the most assessed therapeutic classes of drugs 
were antineoplastic, antidiabetic, antiviral, and 
immunosuppressive medications. Our results also 
indicated that 94% of the trials were multicenter and 
most were phase III studies.
The central position of FUHs in the coordination of 
clinical trials has already been described by Quental & 
Salles. Their study reported that six FUHs coordinated 
22% of 538 trials registered by 20 organizations15. 
The capacity of recruiting research participants and the 
presence of qualified professionals are characteristics 
that make institutions more competitive for clinical 
trials15,16. Considering that FUHs are distinct from other 
non-university hospitals or health services due to their 
research and teaching activities, their researchers’ 
qualifications may explain why these institutions are 
highly sought to coordinate clinical trials despite their 
low participation in the national health care network. 
This hypothesis is further supported by the fact that 
the 4 FUHs that coordinated most clinical trials in our 
study were between the second and fifth positions 
of the national ranking of the CNPq Health Sciences 
Directory of Research Groups5.
The coordination of 75% of the clinical trials was 
performed by 7 hospitals, which may be due to their 
capacity to recruit research participants. Overall, we 
found a positive relationship between the hospital 
assistance profile and the number of coordinated 
trials, but this relationship presented exceptions 
and a high heterogeneity. Some hospitals, such 
as Hospital Universitário da Universidade Federal 
do Maranhão, presented high values of assistance 
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metrics but coordinated only a small number of clinical 
trials, suggesting that other factors might influence 
the dominance of the 7 main hospitals. 
In 2009, the Brazilian federal government provided 
financial support for the establishment of clinical 
research centers in public hospitals. This initiative 
aimed to increase the national capacity of conducting 
clinical research and included the creation of the 
National Clinical Research Network17. Among the 
FUHs analyzed in this study, 13 took part in this 
initiative. Further studies are needed to identify why 
some sponsored FUHs did not engage in research 
activities in this period or, conversely, conducted 
clinical trials without receiving these resources, 
such as Hospital de Clínicas da Universidade 
Federal do Paraná.
In addition, we have found a collaboration 
network among FUHs. This is an important finding 
and it is corroborated by the British experience, 
where the Clinical Research Network has supported 
and coordinated high-quality clinical investigations 
and facilitated the implementation of clinical trials 
in the scope of the National Health Services18. 
Functioning as a network may be an effective 
strategy to overcome challenges and barriers in 
patient recruitment. The adoption of this strategy 
has been proposed by EpecSUS11, and this has 
been an ongoing process.
Our results also showed that the therapeutic classes 
of the studied drugs and the groups of target diseases 
were similar to those reported in other national15 and 
international19 studies. The development of drugs 
that treat progressive chronic diseases has been 
prioritized globally. 
The stage of clinical development of the evaluated 
studies was mainly phase III (69.8%), followed 
by phases II (15.6%), IV (13.1%), and I (1.5%). 
This finding was in accordance with other national 
studies15,20 that have shown the dominance of phase 
III studies. On the other hand, international studies 
have reported different distributions of stages of 
development. According to the analysis of 26 000 
clinical trials registered in the European Federation 
of Pharmaceutical Industries and Associations 
between 2005 and 2010, 32% of these trials were 
phase I, 27% were phase II, and 21% were phase 
IV studies21. Phase III clinical trials are more frequent 
in middle-income countries, probably because they 
demand lower scientific density and present less 
technological risks; in addition, multinational drug 
companies usually prioritize phases I and II trials 
in their home countries17. We did not collect data 
regarding the sponsorship of the analyzed trials due to 
limitations of our search tool. However, other studies 
have reported that clinical trials with registration 
purposes in Brazil are often financially supported by 
multinational pharmaceutical industries15,20.
The large number of phase III studies in FUHs 
suggested that their participation was mostly 
operational, as opposed to the idea that these trials 
are necessarily linked to the scientific competence 
of university hospitals. Brazilian pharmaceutical 
companies have a limited capacity of promoting all 
steps (pre-clinical and phases I-II) of technological 
development and innovation16, whereas phase III trials 
have lower technological requirements and involve 
other competences such as GCP. Clinical investigators 
in Brazil are usually experienced in complying to these 
technical guidelines, which is essential to ensure the 
quality of clinical trial results22.
Clinical trials are the methodological gold standard 
in testing the efficacy and safety of products for 
human health. They are required for the registration 
and commercialization of health products, being 
part of the technological innovation process in the 
health sciences23. Hence, these types of studies 
comprise guidelines and policies related to health, 
science, technology, and innovation and industrial 
development24-26. From an institutional perspective, 
clinical trials qualify professionals and research centers, 
improve assistance, organize health services27, and 
provide new therapeutic options28 even though they 
are a scientific validation step. The participation of 
institutions in these studies should, however, be 
prudent regarding ethical questions on the vulnerability 
of participants29, eventual researchers’ conflicts of 
interests30, and transparency issues31. Especially 
in FUHs, commercial interests in the participation 
in clinical trials raise concerns regarding their lack 
of alignment with academic performance32 and an 
unsatisfactory institutional financial management33.
The limitations of this study include, firstly, the 
lack of information on the trial sponsors, which did 
not allow a thorough interpretation of our findings. 
Secondly, we only analyzed trials coordinated by FUHs, 
and not those in which FUHs were collaborators. 
Finally, although the data collection was performed 
several years ago, we believe that extending the 
study period would not introduce variance that would 
significantly change our findings. 
In summary, we found that FUHs have a leadership 
role in the conduction of clinical trials in Brazil, but 
showed heterogeneity regarding their assistance 
capacities and the number of clinical trials. This could 
be better understood through studies identifying factors 
that influence the creation of diverse institutional 
operational cultures. The predominance of phase III 
trials may be interpreted as a low use of the scientific 
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potentiality of these institutions. The promotion of 
national collaborative studies could help FUHs in the 
establishment of an effective cooperation network 
for improving their capacity of conducting clinical 
trials, especially considering the EpecSUS program.
This article was produced based on a Master’s 
dissertation in Health Innovation and Technology 
Management presented in 2016 to the Teaching and 
Research Institute of Hospital Sírio-Libanês.
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